LA JOLLA, Calif., Jan. 9, 2017 /PRNewswire/ -- DermTech, Inc., the global leader in non-invasive molecular dermatology, announced today that it achieved record sales and sample volume for the 4th quarter of 2016. DermTech processed over 1300 Pigmented Lesion Assay samples in its state-of-the-art CLIA and CAP certified laboratory. The quarterly volume increased from 200 samples in the 1st quarter to over 1300 in the 4th quarter of 2016, representing 550% increase over the period. Each quarter showed significant sequential growth. In addition, the company more that doubled its clinical research products business and added two new large multinational pharmaceutical customers. Other accomplishments in 2016 include the publication of two additional validation studies in top peer reviewed journals and securing $6.7 MM in equity financing. DermTech also completed initial clinical development on a new test for basal and squamous cell cancer and a test for monitoring psoriasis. "The rapid commercial adoption of our PLA assay and research products is due to clinicians and pharmaceutical companies across the country seeing the value of our non-invasive gene expression tests," stated John Dobak, MD, CEO and President of DermTech, Inc. "We will continuing to scale our sales force and laboratory in 2017 to meet this strong demand," he added.
DermTech is the global leader in molecular dermatology. We market and develop non-invasive gene expression tests to aid the clinical diagnosis of skin cancer, assess inflammatory diseases, and to personalize drug treatment. DermTech's technology allows the analysis of skin biopsy samples collected non- invasively using an adhesive patch. Our mission is to transform dermatology by delivering highly accurate, objective information to physicians to improve care and reduce costs. For additional information visit: www.dermtech.com.
Sarah Dennison, MBA
SOURCE DermTech, Inc.